By: Lynn Shapiro 08 October 2010 The anticipated approval of Gardasil [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant, Merck] for women 27 to 45 years of age has thrown the issue of vaccine reimbursement for pharmacists into the spotlight. A Merck spokeswoman told Drug Topics that the company expects to hear […]
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24—45 years: a randomised, double-blind trial
The Lancet, Volume 373, Issue 9679, Pages 1949 – 1957, 6 June 2009 doi:10.1016/S0140-6736(09)60691-7: Munoz, et al Background: Although the peak incidence of human papillomavirus (HPV) infection occurs in most populations within 5—10 years of first sexual experience, all women remain at risk for acquisition of HPV infections. We tested the safety, immunogenicity, and […]
Anaphylaxis following quadrivalent human papillomavirus vaccination.
By: Julia M.L. Brotherton, MD HPH, et al Published at www.cmaj.ca on Sept. 1, 2008. Background: In 2007, Australia implemented the National human papillomavirus (HPV) Vaccination Program, which provides quadrivalent HPV vaccine free to all women aged 12–26 years. Following notification of 7 presumptive cases of anaphylaxis in the state of New South Wales, […]
